EMSy
EMSy is an Italian AI assistant built for prehospital emergency medicine. It combines a source-citing clinical chatbot, hard-coded drug calculators, gamified quiz training and AI-analysed PubMed research for physicians, nurses, paramedics and EMTs.
What is EMSy?
EMSy is a decision-support and continuing-education platform for prehospital emergency care, published by EMSy S.r.l. from Courmayeur, in Italy's Aosta Valley. It was built by two emergency physicians, a nurse and IRC instructor, and a marketing lead, and it targets one occupational group rather than healthcare at large: physicians, nurses, paramedics and the technical operators who staff Italian 118 services and their international equivalents.
The platform rests on four blocks. The AI Assistant answers questions on protocols, pharmacology and complex cases, and cites its sources rather than asserting. The AI Coach, reserved for the top plan, analyses a user's performance and returns targeted study suggestions. Interactive clinical simulations reproduce scenarios drawn from real cases. EMSy Arena turns revision into a game, with daily missions, one-versus-one duels in real time, experience points and a ranking system.
Two further modules sit alongside them. The medical calculators cover pharmacology with fourteen calculators whose formulas are hard-coded rather than produced by a language model, plus manual infusions and families such as cardiovascular, emergency, respiratory and neuromuscular blockers, with a paediatric strand. PubMed Insights filters and summarises new literature by relevance threshold and by category, from trauma and toxicology to ultrasound and mountain rescue. A medical blog written by clinicians adds more than ninety articles.
Protocol coverage follows ACLS under the ERC 2025 guidelines, PALS, ATLS, ITLS and PHTLS, alongside toxicological and environmental emergencies. The vendor develops no model of its own: it routes requests automatically to third-party models from Anthropic, Google DeepMind, OpenAI and Mistral AI through the OpenRouter gateway, choosing the model according to the complexity of the request.
EMSy is explicit about what it is not. Its terms, its AI policy and its homepage all state that the service is not a medical device under the EU Medical Device Regulation, that it does not replace clinical judgement, and that using it to reach a diagnosis on an individual case is prohibited. Access is limited to qualified professionals aged eighteen or over. The interface runs in Italian and English, in a browser or through an Android application; iPhone users are pointed to a web app instead.
What it does
- Question a specialised AI assistant about a protocol, a drug or a complex clinical case, with sources cited in the answer
- Compute emergency and paediatric drug doses and manual infusion rates using calculators whose formulas are hard-coded rather than generated
- Train through interactive quizzes, realistic clinical simulations and one-versus-one duels in EMSy Arena
- Follow emergency-medicine literature through PubMed Insights, filtered by relevance score and clinical category
- Get personalised study suggestions and performance feedback from the AI Coach on the top plan
- Dictate clinical notes by voice, transcribed in real time and not retained afterwards
- Upload a PDF, DOCX or image, including scanned documents handled by server-side OCR, and have the assistant analyse it
When to use EMSy / When not to
A quick filter to help you decide if EMSy is the right fit.
When to use EMSy
- Emergency physicians working on ambulances, rapid-response cars and helicopter services who need protocols at hand during an intervention
- Emergency and critical-care nurses who want a single place to refresh drug doses, scores and resuscitation algorithms
- Paramedics, EMTs and specialised technical operators trained on Italian 118 or international prehospital protocols
- Clinical instructors and nurse educators looking for ready-made quizzes, clinical simulations and progress tracking for their trainees
- Medical students and residents specialising in emergency medicine who want structured revision plus a curated feed of new literature
When not to use EMSy
- Anyone outside the healthcare professions: the terms restrict the service to qualified professionals and to users aged 18 or over
- Clinicians looking for a diagnostic tool, since the vendor states repeatedly that EMSy is not a medical device and must not drive decisions on individual cases
- Teams that need to embed the tool in an EHR or dispatch system, as there is no public API and no third-party integration today
- Hospitals or services that require a signed data processing agreement or a published security certification before purchasing
- iPhone-first users expecting a native App Store application, since the vendor directs them to install a web app instead
How to use EMSy
A typical end-to-end flow, from setup to results.
- Open the site in Italian or English, the two interface languages the platform actually offers
- Create a free account, which is required before any feature becomes available
- Start on the Free Basic plan: thirty AI messages a month, two file attachments a day and two daily Arena missions
- Ask the AI Assistant about a protocol, a drug or a case, and follow the sources it cites
- Attach a PDF, DOCX or image when a document needs to be read, including scanned files handled by OCR
- Use the pharmacology and infusion calculators for doses, checking the paediatric options where relevant
- Train in EMSy Arena through daily missions, simulations and duels against other professionals
- Browse PubMed Insights and narrow the feed by relevance threshold and clinical category
- Install the Android application from Google Play, or add the web app to the home screen on an iPhone
- Start a fourteen-day free trial of Premium or Professional from the pricing page when the free quotas run out
Pros & Cons
Pros
- Narrow, deliberate specialisation in prehospital emergency care, covering both Italian 118 practice and international protocols
- Answers cite their sources, and a dedicated literature module keeps the clinical evidence in view
- Legal and AI documentation is far more detailed than usual at this scale: privacy notice, terms, cookie policy, AI policy and a dated sub-processor table
- Contractual no-training commitment across every model provider, with patient data excluded from external processing
- Calculator formulas are hard-coded rather than generated by a language model, which removes one class of error
- A permanent free plan and a low paid entry point at 7.99 EUR per month, with a fourteen-day trial
- Regulatory position stated openly: not a medical device, not a high-risk AI system, not a GPAI provider
Cons
- No public API and no third-party integration; the vendor's own FAQ presents integration as a future possibility
- No published security certification of any kind across the pages collected, neither ISO 27001 nor SOC 2
- No data processing agreement offered to customers; only the sub-processors' own agreements are linked
- No native iOS application for this product, with iPhone users redirected to a web app
- The continuing-education certifications advertised on the Professional plan are marked as still in development
- A very young and very small publisher: the company was registered in September 2025 and declares five employees
- Written contact only, through info@emsy.io or a form; no telephone number is published on the site
Pricing & Plans
A permanent free plan is available. EMSy Basic costs nothing and requires no payment card, offering thirty AI messages per month, two attachments per day and two daily Arena missions. The cheapest paid entry point is EMSy Premium at 7.99 EUR per month, currently carrying an Early Bird badge, followed by EMSy Professional at 14.99 EUR per month. Both paid plans include a fourteen-day free trial. The pricing page opens on its monthly view and offers an annual view advertised as saving 17 per cent, although no annual amount is published. Payments are handled by Stripe, and subscriptions are managed on the website rather than through the Android application.
- 30 EMSy AI messages per month
- 2 AI attachments per day (PDF
- DOCX
- images)
- 2 daily missions on EMSy Arena
- unlimited blog access
- free access to PubMed Insights
- everything in Free Basic
- unlimited EMSy AI
- unlimited AI attachments
- unlimited EMSy Arena
- Targeted Learning
- duels enabled
- priority email support
- 14-day free trial
- everything in Premium
- EMSy AI with Deep Analysis
- EMSy Arena with AI Coach
- ECM certifications (in development)
- training certification with digital badge
- complete professional analytics
- dedicated priority support
- 14-day free trial
Data, GDPR & hosting
A consolidated view of how EMSy handles your data.
GDPR overview
GDPR implementation is documented in unusual detail for a company of this size. The privacy notice, dated 20 May 2026, sets out a legal basis for each purpose, names a Data Protection Manager, and lists retention periods category by category. A dedicated sub-processor page, last updated on 14 July 2026, tabulates every vendor with its GDPR role, purpose, data categories, location and legal basis. Transfers outside the EEA rely on the EU-US Data Privacy Framework for Vercel, Stripe and Google, and on standard contractual clauses with a transfer impact assessment for OpenAI, Anthropic and Pinecone. Users exercise Articles 15 to 22 rights at info@emsy.io with a thirty-day response commitment, and may complain to the Italian Garante. The FAQ states outright that EMSy is fully compliant with European and Italian privacy law.
Who owns the data?
The data controller is EMSy S.r.l., based at Via degli Anziani 14 in Courmayeur, Italy, with Simon Grosjean named as Data Protection Manager and info@emsy.io as the privacy contact. The company keeps ownership of the platform and of its proprietary content, while the text a user types remains that user's content. Personal data is shared only with named processors acting under Article 28 agreements, among them Vercel, Stripe, Google, OpenAI, Anthropic, Pinecone, Mistral AI and Brevo. The privacy notice states that user content is not used to train third-party models and that patient data is never passed to external providers.
Reuse rights
Users keep control of what they submit and may exercise the full set of GDPR rights, including access, rectification, erasure, restriction, portability and objection, by writing to info@emsy.io; the company undertakes to answer within thirty days. Consent given for analytics or marketing can be withdrawn at any time through the cookie preferences link, and users can object to the light profiling applied to gamification and leaderboards. Platform content itself is another matter: the terms reserve all rights over the services and proprietary material to EMSy and its licensors, and prohibit unauthorised reproduction, modification or distribution. Reuse of EMSy's own content therefore requires permission, while the user's own submissions do not.
Data retention & training
Hosting summary
Hosting and application delivery are handled by Vercel, Inc., with a location the vendor describes as EU and US and a stated preference for EU regions. The privacy notice confirms that European regions are prioritised where available, alongside pseudonymisation and minimisation measures. Model inference is distributed: OpenAI runs in the US and EU on specific endpoints with zero data retention where available, Anthropic in the US, Pinecone in the US and EU, while Mistral AI performs document OCR on European infrastructure in Paris and Brevo handles email from France. Stripe and Google operate across the EU and the US. Transfers outside the European Economic Area rely on the EU-US Data Privacy Framework for Vercel, Stripe and Google, and on standard contractual clauses with a transfer impact assessment and supplementary technical measures for the others. Declared safeguards include encryption in transit and at rest where applicable, access controls, logging, hardening, backups, environment segregation and periodic vendor review.
Things to keep in mind
Risks and trade-offs to weigh before adopting EMSy.
- Automation bias is the central risk: a fluent, source-citing answer under time pressure invites the reader to stop checking, exactly when the vendor insists clinical judgement must remain the professional's own
- The publisher's own statements about its age do not agree: its llms.txt claims a 2024 founding and the footer a 2025 copyright, while the Italian business register records the company only from 9 September 2025
- The structured data on the site advertises social accounts that do not exist, with the LinkedIn and X links in its JSON-LD both returning 404 while the real accounts are those in the page footer
- The privacy notice claims to cover a native app for Android and iOS, yet no iOS application exists for this product and the site itself redirects iPhone users to a web app
- No security certification is published anywhere and no data processing agreement is offered to customers, which limits what an employer can verify before allowing clinical use
- Long-term reliance on gamified revision can flatter competence: points, streaks and rankings measure engagement with the quiz format, not readiness at a real scene
- The publisher also sells a separate product, EMSy Events, on another domain and with its own iOS application, which is easy to mistake for this platform when searching app stores
Setup & Integrations
Technical difficulty
Setup is trivial. There is nothing to install, deploy or configure: a free account is created on the site and the platform is used immediately in a browser. An Android application can be downloaded from Google Play, and iPhone users add the web app to their home screen. No API has to be connected and no connector configured, since none exist. The only friction is administrative: the vendor reserves the right to apply reasonable checks on the declared professional status and on the user's age before granting access.
Deployment
Apps stores
Supported languages
Behind EMSy
Social
Resources
All the official URLs gathered for verification and reference.
Frequently asked questions
Who is EMSy designed for?
Can EMSy replace clinical judgement?
Is there a free plan?
How much do the paid plans cost?
Is my content used to train AI models?
Which languages does the platform support?
Is there a mobile application?
Does EMSy offer an API or integrations?
Who publishes EMSy?
How long is data kept?
Should you pick EMSy?
EMSy is a deliberately narrow product, and that is its main strength. Instead of offering a general medical assistant, it addresses one occupational group, prehospital emergency responders, and equips it with the specific things that group uses in the field: protocol answers that cite their sources, drug calculators whose formulas are hard-coded rather than generated, gamified revision, and a filtered feed of new literature. The regulatory posture is unusually clear for the category. The vendor states plainly that the tool is not a medical device, that it must not drive decisions on an individual case, and that it develops no model of its own; its legal and AI documentation, including a dated sub-processor table and a contractual no-training commitment, is more thorough than most vendors of comparable size manage.
The reservations are those of a very young company. EMSy S.r.l. was registered in September 2025 and declares five employees; the site still labels its testimonials as beta-tester reviews and its entry-level price as an Early Bird rate. There is no public API and no integration with clinical software, so the tool sits beside a practitioner's existing systems rather than inside them. No security certification is published anywhere on the site, no data processing agreement is offered to customers, and the continuing-education certifications promised on the top plan are still marked as in development. iPhone users get a web app rather than a native application.
For an individual clinician or responder, the free plan and the 7.99 EUR entry point make the tool cheap to evaluate on its merits. For a service or hospital planning a procurement, the missing certifications, the absent contractual guarantees and the youth of the publisher are the questions to settle first.
- Choosing a selection results in a full page refresh.
- Opens in a new window.